Business Wire

Biogen to Present Data at Alzheimer's Association International Conference® 2017 (AAIC®)

Jaa

Biogen (NASDAQ: BIIB) will present data from its Alzheimer’s disease programs at the Alzheimer's Association International Conference® 2017 (AAIC®) in London, July 16 - 20, 2017.

The planned poster presentations include:

  • Change from Baseline in Clinical Dementia Rating Scale Cognitive and Functional Domains in PRIME, a Randomized Phase 1b Study of the Anti-Amyloid Beta Monoclonal Antibody Aducanumab (BIIB037). Poster 1-053: July 16, 2017, 9:30 a.m. GMT+1. This new post-hoc analysis shows the change in the cognitive and functional subscores, which are derived from the previously reported clinical dementia rating (CDR) score for the overall and early Alzheimer’s disease populations in the 1, 3, 6 and 10 mg/kg aducanumab fixed-dosing cohorts in Phase 1b.

    This poster will be available concurrently with the session on the Investors section of the Biogen company website, www.Biogen.com.
  • Signs and Symptoms of Alzheimer’s Disease Noted in Health Records up to 5 Years Prior to Diagnosis . Poster 2-275: July 17, 2017, 9:30 a.m. GMT+1. This analysis reports the documentation of cognitive and behavioral impairment from U.S. medical health records, prior to an Alzheimer’s disease diagnosis.

About Aducanumab

Aducanumab (BIIB037) is an investigational compound being developed for the treatment of early Alzheimer’s disease. Aducanumab is a human recombinant monoclonal antibody (mAb) derived from a de-identified library of B cells collected from healthy elderly subjects with no signs of cognitive impairment or cognitively impaired elderly subjects with unusually slow cognitive decline using Neurimmune’s technology platform called Reverse Translational Medicine (RTM). Biogen licensed aducanumab from Neurimmune under a collaborative development and license agreement.

About Biogen

Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. Founded in 1978, Biogen is a pioneer in biotechnology, and today the company has the leading portfolio of medicines to treat multiple sclerosis; has introduced the first and only approved treatment for spinal muscular atrophy; and is at the forefront of neurology research for conditions including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis. Biogen also manufactures and commercializes biosimilars of advanced biologics. For more information, please visit www.biogen.com. Follow us on social media – Twitter, LinkedIn, Facebook and YouTube.

Biogen Safe Harbor

This press release contains forward-looking statements, including statements relating to the development and potential benefits, safety and efficacy of investigational drugs, including aducanumab and results of certain clinical studies. These statements may be identified by words such as “believe,” “except,” “may,” “plan,” “potential,” “will” and similar expressions, and are based on our current beliefs and expectations. You should not place undue reliance on these statements or the scientific data presented. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. Factors which could cause actual results to differ materially from our current expectations include the risk that we may not fully enroll our clinical trials or enrollment will take longer than expected, unexpected concerns may arise from additional data or analysis, including data, analysis or results obtained during our clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates, or we may encounter other unexpected hurdles which may be impacted by, among other things, the occurrence of adverse safety events, failure to obtain regulatory approvals in certain jurisdictions, failure to protect intellectual property and other proprietary rights, product liability claims, third party collaboration risks, and the other risks and uncertainties that are described in the Risk Factors section of Biogen’s most recent annual or quarterly report and in other reports Biogen has filed with the U.S. Securities and Exchange Commission. Any forward-looking statements speak only as of the date of this press release and we assume no obligation to update any forward-looking statement.

Contact information

Biogen
MEDIA CONTACT:
Catherine Falcetti, +1 781-464-3260
public.affairs@biogen.com
or
INVESTOR CONTACT:
Matt Calistri, +1 781-464-2442
IR@biogen.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

GTIS Partners Clinches Sustainability Performance Top Honors for Third Year Running20.9.2017 16:32Tiedote

GTIS Partners LP (“GTIS”), a real estate private equity firm headquartered in New York City, with offices in São Paulo, Los Angeles, San Francisco, Atlanta, Paris and Munich, today announced that the GTIS Brazil Real Estate Fund I has been recognized as 2017’s most sustainable private equity real estate investment fund in South America by the Global Real Estate Sustainability Benchmark (GRESB). This is the third year in a row that the fund has taken top honors. In addition, GRESB awarded GTIS Brazil Real Estate Fund II first place in the specialized category of non-listed real estate funds with hotel concentrations, and a number two ranking overall. GTIS Brazil Real Estate Fund III, which held its final closing in December 2016 with approximately $680 million in commitments, took third place. “GTIS Partners received another top honor with the #1 rank for South America in the

The Meet Group to Acquire LOVOO20.9.2017 15:31Tiedote

The Meet Group, Inc. (NASDAQ:MEET), a public market leader in the mobile meeting space, today announced it has executed a definitive agreement to acquire LOVOO, a social dating app, for $70 million in cash, inclusive of a $5 million contingent earn-out. This acquisition furthers The Meet Group’s strategy to innovate, acquire, and build the largest mobile portfolio of brands for meeting new people. The LOVOO acquisition is expected to expand The Meet Group’s global footprint, increase the company’s scale and profitability, and diversify its business model by adding expertise in subscription and in-app purchasing. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170920005645/en/ LOVOO is a social and mobile technology company based in Germany: The #1 Dating App in German speaking countries (Ger

Arthur D. Little Urges Network Operators to Prepare for Next-Generation Internet of the GigaWorld20.9.2017 14:00Tiedote

In its new report, “Unlocking GigaWorld Innovation: GigaApps in a GigaWorld,” Arthur D. Little (ADL) outlines the investment and monetization opportunities available to network operators ready to embrace the “GigaWorld”, the emerging third cycle of the internet. Defined by continuous and intelligent collaboration between individuals, devices and the built environment – and driven by applications in the areas of augmented reality, virtual telepresence and automated living – the GigaWorld has the potential to both power our economy and change the way we live. However, for it to be fully realized, network operators need to deliver improved Quality of Experience (QoE) for consumers and new Quality of Service (QoS) features for content and service providers. While operators have focused on delivering sufficient bandwidth and coverage to drive the current iteration of the internet, the GigaWorld

LINTEC Announces Four New Adhesive Materials for Labels20.9.2017 13:45Tiedote

LINTEC Corporation (TOKYO: 7966) announced on September 20 that it will launch four newly developed label adhesive materials sequentially from October 2017. The new products will be on display prior to launch at Labelexpo Europe 2017, the world’s largest trade show in the label field. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170920005611/en/ LINTEC's super-strength adhesive labelstocks (Photo: Business Wire) Overview of Labelexpo Europe 2017 Date: September 25 (Mon.) to 28 (Thurs.) Venue: Brussels Expo, Belgium LINTEC Booth: Hall 3 3C 15 LINTEC Press Conference: 11:00 a.m. to 11:30 a.m., September 25, held in the Brussels Expo Press Office Theater Super-strength adhesive labelstocks: Extreme adhesion for rough surfaces Charac

EGS Invests in Artificial Intelligence from Quintiq20.9.2017 13:05Tiedote

Quintiq, a Dassault Systèmes brand and global leader in supply chain planning and optimization (SCP&O), announces that it has partnered with European Gateway Services (EGS) to bring a new level of intelligence to intermodal logistics. European Gateway Services (EGS) offers the market an integrated network for transport to and from the European hinterland. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170920005578/en/ EGS invests in artificial intelligence from Quintiq (Photo: Business Wire) To better support its customers, EGS takes standard planning strategies to a new level with a synchromodal trip optimizer using Quintiq’s planning and optimization software, which employs artificial intelligence to choose the optimal modes and routes at all times. Quintiq technology makes s

EchoStar 105/SES-11 Shipped from Toulouse to the Cape for SpaceX Launch20.9.2017 12:03Tiedote

SES, EchoStar Corp., and Airbus Defence and Space announced today that the new EchoStar 105/SES-11 spacecraft, built by Airbus, has been shipped from the Airbus facilities in Toulouse, France, to Cape Canaveral, Florida, for its forthcoming launch by SpaceX in October. The first satellite that EchoStar has constructed with manufacturer Airbus, EchoStar 105/SES-11 will be launched by SpaceX on a flight-proven Falcon 9 rocket from Launch Complex 39A at Kennedy Space Center, Florida. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170920005539/en/ EchoStar 105/SES-11 Shipped from Toulouse to the Cape for SpaceX Launch (Photo: Business Wire) EchoStar 105/SES-11, a high-powered hybrid Ku and C-band communications satellite, is a dual-mission satellite for US-based operator EchoStar and Luxembourg-based

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme